REG - Theracryf PLC - Director/PDMR Shareholding

TheracryfAnnouncement

04/03/2025 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250304:nRSD3118Za&default-theme=true

RNS Number : 3118Z  Theracryf PLC  04 March 2025

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Director/PDMR Shareholding

Alderley Park, UK - 4 March 2025: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on oncology and neuropsychiatry has been
notified that Dr Helen Kuhlman, Chief Business Officer has
purchased 1,500,000 Ordinary Shares of 0.25 pence each ("Ordinary Shares")
at a price of 0.24 pence per Ordinary Share.

The notifiable interest of Dr Helen Kuhlman is now 2,555,744 Ordinary
Shares, representing 0.5% of the issued Ordinary Share capital of the
Company.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Dr Helen Kuhlman
 2   Reason for notification
 a.  Position/Status                                              Chief Business Officer (PDMR)
 b.  Initial notification/ Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         TheraCryf plc
 b.  LEI                                                          213800NO3E6TSTQO8K20
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

                                                            Ordinary Shares of 0.25p each

Identification Code

                                                                  GB00BSVYN304
 b.  Nature of the transaction                                     Purchase of Ordinary Shares
 c.  Price(s) and volume(s)

Price(s)    Volume(s)
                                                                  0.24 pence  1,500,000

 
 d.  Aggregated information

     - Aggregated Volume                                          As above

     - Price
 e.  Date of the transaction                                       4 March 2025

 
 f.  Place of the transaction                                      XLON

 

d.

Aggregated information

- Aggregated Volume

- Price

 

As above

e.

Date of the transaction

  4 March 2025

 

f.

Place of the transaction

 XLON

 

 

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

 enquiries@theracryf.com
 Dr Huw Jones, CEO

Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD & Joint Broker)            +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Turner Pope Investments (Joint Broker)                      +44 (0)20 3657 0050

 James Pope / Andy Thacker
 Vigo Consulting                                             +44 (0)20 7390 0231

                             theracryf@vigoconsulting.com
 Rozi Morris

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(http://www.theracryf.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAFDLESPSEFA